As of Nov 20, 2026, 1 of 1 active firms rate INAB a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
INAB EPS & revenue forecast
EPS · NEXT QUARTER
$-0.33
Range $-0.33 – $-0.33 · 1 analysts · +27% YoY
Next period, 1 analysts expect In8bio Inc to earn $-0.33 a share (range $-0.33 – $-0.33), versus $-0.26 a year earlier. Full-year consensus is $-1.12, growing to $-0.98 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $1.7M next year.
Top analysts covering In8bio Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on INAB.
#1
Swayampakula Ramakanth
HC Wainwright & Co. · Rank #321
Buy
$6.00+679.2% to target
Overall win rate
38%
+ Follow
#2
SR
Soumit Roy
Jones Trading
Buy
$1.20+55.8% to target
Coverage
—
+ Follow
INAB stock forecast FAQ
What is INAB's average 12-month price target?+
The 1 active firms with a live target average $6.00 for In8bio Inc over the next 12 months, ranging from a $6.00 high to a $6.00 low, as of Nov 20, 2026.
Is INAB stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 1 active firms as of Nov 20, 2026, 1 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover INAB?+
1 active firms have a recognized rating on In8bio Inc as of Nov 20, 2026, and 1 active firms carry a live 12-month price target.
Who is the most accurate analyst covering INAB?+
Among analysts who currently cover INAB, Swayampakula Ramakanth of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #321). Their current call is Buy with a $6.00 target.
What is In8bio Inc's projected EPS for next quarter?+
The consensus estimate is $-0.33 per share (range $-0.33 – $-0.33) across 1 analysts. Full-year EPS is projected at $-1.12, rising to $-0.98 the following year.
How much revenue is In8bio Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $1.7M next year.
Have analysts been upgrading or downgrading INAB lately?+
As of Nov 20, 2026, 1 of 1 active firms rate INAB a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their INAB calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.